All In Biotech

Drug Trial Radar · NCT06278389

Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants

Study of Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants in China: A Single-center, Randomized, Double-blind, Placebo-controlled, Two-Stage Trial

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jan 24, 2024

Primary completion

May 20, 2024

Study completion May 20, 2024

Sponsor

Sponsor type
Industry
Collaborators
Chengdu Aidea Pharmaceutical Technology Co., Ltd
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to investigate the safety and tolerability of single ascending dose ACC017 tablets in Chinese healthy adult participants. This study aims to address the following major questions: * Recommended dosage for ACC017 tablets used in phase Ib/IIa trial; * The pharmacokinetic (PK) characteristics of single dose ACC017 tablets; * The effect of food (FE) on the PK of ACC017 tablets; * Drug-drug interactions (DDIs) when ACC017 tablets are co-administered with emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) tablets (II).

Conditions

  • Healthy Adult Participants

Interventions

  • ACC017 tabletsDrug

    ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo

  • Emtricitabine and Tenofovir Alafenamide Fumarate TabletsDrug

    Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency, causality, severity, and expectedness of adverse events (AEs)Time frame: Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
  2. ACC017 PK parameter: Cmax (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  3. ACC017 PK parameter: C24h (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  4. ACC017 PK parameter: AUC0-t (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  5. ACC017 PK parameter: AUC0-∞ (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  6. ACC017 PK parameter: Tmax (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  7. ACC017 PK parameter: t1/2 (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  8. ACC017 PK parameter: Vz/F (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  9. ACC017 PK parameter: CL/F (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  10. ACC017 PK parameter: λz (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  11. ACC017 PK parameter: AUC_%Extrap (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  12. ACC017 PK parameter: MRT0-t (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
  13. ACC017 PK parameter: MRT0-∞ (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.